What L2P Research Labs does

L2P Research Labs is a preclinical contract research organization (CRO) that provides integrated research services for pharmaceutical and biotechnology sponsors pursuing Investigational New Drug (IND) applications, with a primary focus on oncology and immuno-oncology. The company operates AAALAC-accredited and GLP-compliant audited facilities at 25 Health Sciences Drive in Stony Brook, New York, with a legal registered address in Annville, Pennsylvania. Its service portfolio centers on IND-enabling studies, efficacy studies, and advanced preclinical imaging, supported by proprietary orthotopic and metastases tumor models, patient-derived xenograft (PDX) models, and imaging modalities including whole body animal imaging, small animal ultrasound and MRI, and CT scanning. The company's operations span over 15 laboratory animal species across two facilities, with LIMS-integrated study data management ensuring standardized study design, conduct, analysis, reporting, and a 10-year data archival requirement.

L2P sells to enterprise pharmaceutical and biotechnology clients through direct B2B engagement, addressing the translation research gap between proof-of-concept and clinical trials via a fee-for-service, project-specific pricing model typical of professional services CROs. Its primary customer segments are pharmaceutical and biotechnology companies, with academic research institutions as a secondary segment. The company's value proposition is built on regulatory-grade facility accreditation, proprietary tumor model libraries, advanced imaging capability bundled with study execution, and standardized digital workflows that reduce sponsor friction during IND preparation.

L2P was founded in 2015 by Dr. Anaganti, who brings 15+ years of pharmaceutical industry experience including tenure at the National Cancer Institute (NIH) and the International Agency for Research in Cancer (IARC-WHO), with specialization in preclinical development and GxP compliance. On November 6, 2025, NJ Bio, Inc. announced the asset purchase and full integration of L2P Research Labs' services into its translational research platform, making L2P a subsidiary of NJ Bio. Prior to the acquisition, L2P operated with 11–50 employees as an independent private company.

Name

L2P Research Labs

Legal name

L2P Research, LLC

Website

https://l2plabs.com

Company type

Private

Founded year

2015

Operating status

Acquired

Headcount range

11–50 employees

Short description

L2P Research Labs is a preclinical contract research organization providing IND-enabling studies, proprietary tumor models, and advanced imaging services to pharmaceutical and biotechnology sponsors, with a primary focus on oncology research, operating from AAALAC-accredited and GLP-compliant facilities in Stony Brook, New York.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Preclinical contract research
• IND-enabling studies
• Oncology drug development
• Animal model services
• Preclinical imaging services

Headquarters

HQ city

Stony Brook

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Contract Research Services: Fee-for-service contract research model providing preclinical and early-phase clinical research services to pharmaceutical and biotech companies. Services include IND-enabling studies, efficacy studies, immuno-oncology models, and advanced imaging services.

Go-to-market motion1 record

Distribution channels1 record

Core offering

L2P Research Labs is a preclinical contract research organization (CRO) providing integrated research services to support Investigational New Drug (IND) applications. The company delivers IND-enabling studies, efficacy studies, immuno-oncology models, advanced preclinical imaging, and proprietary tumor model services from AAALAC-accredited and GLP-compliant facilities in Stony Brook, New York, primarily serving pharmaceutical and biotechnology companies in oncology drug development.

Product overview

L2P Research Labs was a preclinical contract research organization (CRO) providing integrated research services for Investigational New Drug (IND) applications, primarily focused on oncology and immuno-oncology research. The company operated GLP-compliant and AAALAC-accredited facilities in Stony Brook, New York, offering proprietary tumor models, efficacy studies, imaging services, and IND-enabling studies. L2P Research Labs was acquired by NJ Bio, Inc. in November 2025 through an asset purchase and full integration.

Differentiator

Problem solved

Functional benefit

Products and services

• Preclinical Contract Research Services (IND-Enabling Studies)
• Early-Phase Clinical Research Services
• Proprietary Orthotopic and Metastases Tumor Model Studies
• PDX Tumor Model Studies
• Preclinical Imaging Services

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• NJ BiomajorStrategic or Co-development Partner · 6 November 2025NJ Bio announced the asset purchase and full integration of L2P Research Labs' services to expand its translational research offerings. This acquisition enhances NJ Bio's capabilities in preclinical and early-phase clinical research, particularly in oncology.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Fortrea (formerly Labcorp Drug Development): Full-service CRO providing preclinical through clinical research services including GLP toxicology and IND-enabling studies. Overlaps with L2P's preclinical CRO offerings as part of a much broader portfolio.
• Charles River Laboratories: Large-scale preclinical CRO offering GLP-compliant toxicology, safety assessment, tumor models, and IND-enabling programs across all therapeutic areas. Overlaps with L2P's preclinical CRO services but at significantly broader scale.
• Eurofins Scientific: Global testing services provider with significant preclinical and biopharma product testing capabilities. Overlaps with L2P's laboratory testing and preclinical research services as part of a much broader services portfolio.
• WuXi AppTec: Global CRO/CDMO providing preclinical safety, DMPK, tumor biology, and IND-enabling services. Comparable to L2P's preclinical CRO services but at substantially larger global scale.
• The Jackson Laboratory: Non-profit biomedical research institution providing preclinical mouse model services, tumor models, and translational research support. Comparable to L2P's tumor model and preclinical oncology capabilities.

Direct peers

• Inotiv: Preclinical CRO and research models provider offering toxicology, safety assessment, and animal model services with GLP-compliant facilities. Directly comparable to L2P's IND-enabling preclinical research offerings.
• Crown Bioscience: Preclinical oncology CRO offering proprietary tumor models (including PDX and orthotopic), immuno-oncology services, and IND-enabling studies. Closely comparable to L2P's oncology preclinical CRO model with global scale advantage.
• Champions Oncology: Preclinical CRO specializing in patient-derived xenograft (PDX) tumor models and oncology drug development services. Directly comparable to L2P on PDX and orthotopic oncology model offerings and biotech sponsor base.
• Oncodesign Services: European preclinical CRO specializing in oncology drug discovery, tumor models, and translational research services. Comparable to L2P's oncology preclinical CRO focus and proprietary model approach.

Emerging players

• Bionova Scientific: Emerging biopharma CDMO/CRO with preclinical biologics testing and manufacturing services. Comparable as a smaller, specialized preclinical services provider serving biotech sponsors with GLP-compliant offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about L2P Research Labs